<?xml version="1.0" encoding="Windows-31J"?>
<ArticleSet xmlns="http://www.openarchives.org/OAI/2.0/">
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-0904</Issn>
      <Volume>13</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Maturity-Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report</ArticleTitle>
    <FirstPage LZero="delete">e70173</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mihiro</FirstName>
        <LastName>Sue</LastName>
        <Affiliation>Department of Diabetology and Metabolism, NHO Okayama Medical Center </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayu</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Diabetology and Metabolism, NHO Okayama Medical Center </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Diabetology and Metabolism, NHO Okayama Medical Center </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Diabetology and Metabolism, NHO Okayama Medical Center </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sanae</FirstName>
        <LastName>Teshigawara</LastName>
        <Affiliation>Department of Internal Medicine, Diabetes Center, Okayama Saiseikai General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Department of Diabetology and Metabolism, NHO Okayama Medical Center </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Department of Diabetology and Metabolism, NHO Okayama Medical Center </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Izumi</FirstName>
        <LastName>Iseda</LastName>
        <Affiliation>Department of Diabetology and Metabolism, NHO Okayama Medical Center </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Hida</LastName>
        <Affiliation>Department of Diabetology and Metabolism, NHO Okayama Medical Center </Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This report describes the first case of maturity-onset diabetes in young (MODY) with HNF1B mutation started administration of the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, tirzepatide. A 26-year-old female with a 15-year history of diabetes mellitus was diagnosed with MODY, which is characterized by decreased insulin secretion. She was treated with tirzepatide, which significantly improved her glycemic management; insulin secretion increased the fasting serum C-peptide immunoreactivity from 0.36 to 1.09&#8201;ng/mL. The patient discontinued glimepiride, and her total daily insulin dose was reduced from 88 to 4&#8201;units. This report highlights the glucose-lowering effects of tirzepatide in a patient with MODY who has the HNF1B p.Glu105Lys mutation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">glucagon-like peptide-1 (GLP-1)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">glucose-dependent insulinotropic polypeptide (GIP)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">maturity-onset diabetes in young (MODY)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tirzepatide</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-0904</Issn>
      <Volume>13</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Crowned Dens Syndrome Triggered by Dental Treatment</ArticleTitle>
    <FirstPage LZero="delete">e70168</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Soejima</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Crowned dens syndrome (CDS) is an important yet often overlooked cause of fever and neck pain, frequently leading to unnecessary examinations and treatments and misdiagnosis as infectious diseases or rheumatic diseases. The mechanism of an acute attack of CDS is not clarified completely, while it is considered that severe systemic stress can trigger inflammation caused by calcium pyrophosphate crystals. We describe a case of CDS triggered by localized physical stress to the neck and emphasize the importance of considering this condition in cases of fever and neck pain following dental treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">calcium pyrophosphate crystal deposition disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">crowned dens syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dental treatment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fever</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neck pain</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
</ArticleSet>
